Zofingen, 11 January 2013 -- At the Shareholders’ Meeting scheduled for 18 April 2013, the Board of Directors of
Siegfried Holding AG (SIX: SFZN) will propose the appointment to the Board of Colin
Bond, Chief Financial Officer of Evotec AG.
Colin Bond, 52, is a citizen of Great Britain and Switzerland. In 2010, he joined Hamburg-
based Evotec AG as group Chief Financial Officer and member of the management board.
The company is listed on the Frankfurt Stock Exchange as part of TecDax and provides a
wide range of research and development services in the field of pharmaceutical ingredients.
Following career stations as a pharmacist, chartered accountant and management consult-
ant, he worked for 25 years as Chief Financial Officer for several international companies in
various industries, of which 11 years for Great Lakes Chemical Corporation, today Chemtura,
a US-based global specialty chemicals company.
Colin Bond holds a university degree in pharmacy from the University of Aston, Birmingham,
and a MBA degree from London Business School.
Gilbert Achermann, Chairman of Siegfried’s Board of Directors: “We are very happy to pro-
pose to our Board such a convincing entrepreneur as Colin Bond. He will represent a valua-
ble addition to the Board thanks to his profound experience in the finance sector and in the
pharmaceutical industry, his proven capacity for strategic thinking, and his international con-
For further information:
Peter Gehler, Head Corporate Center
Tel. +41 (0)62 746 11 44
Mobile +41 (079) 416 41 16
Fax +41 (0)62 746 11 03
Siegfried Holding AG
Untere Brühlstrasse 4
The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, Malta and the USA. At the end
of 2011, Siegfried reported annual sales of CHF 328 million and employs at the time being approximately 800 employees. Siegfried Holding AG is
listed on the Swiss Exchange (SIX: SFZN).
Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingre-
dients for the research-based pharmaceutical industry as well as the corresponding intermediate steps and controlled substances, and provides
development and production services for drugs in finished dosage forms including sterile filling.
Cautionary Statements Regarding Forward-looking Statements
This press release may contain forward-looking statements based on current assumptions and forecasts made by Siegfried Group management
and other information currently available to the Siegfried Group. Various known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation, development or performance of the company and the estimates given
here. Siegfried Holding AG does not intend, and does not assume any liability whatsoever, to update these forward-looking statements or to
conform them to future events or developments.